CompletedNot Applicable

New Dermal Filler for Chin Correction and Augmentation

Canada140 participantsStarted 2021-01-29

Plain-language summary

Randomized, evaluator-blinded, no treatment controlled multicenter study to evaluate safety and effectiveness of GP0109 for augmentation and correction or retrusion in the chin region in Canada

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * subject willing to comply with the requirements of the study * subject intent to receive treatment for augmentation and correction of retrusion in the chin region * subject with mild or moderate (grade 1 or 2) on the GCRS Exclusion Criteria: * subjects presenting with know allergy to HA (hyaluronic acid) filler or amide local anesthetics * subjects with any previous facial surgery below the nasal line or previous HA filler or collagen below the nasal line within 12 months * subjects in any other interventional clinical study within 30 days before baseline

What they're measuring

Responder rate based on the Galderma Chin Retrusion Scale as assessed live by the Blinded Evaluator

Timeframe: 3 months after baseline

Trial details

NCT IDNCT04631263

SponsorGalderma R&D

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2021-09-09

View on ClinicalTrials.gov More Chin Augmentation and Correction trials